.INVESTIGATION HIGHLIGHT.06 August 2024.
A big randomized regulated trial along with cisgender ladies highlights the difficulties of adherence to a daily oral preexposure treatment program as well as illustrates that twice-yearly injection of lenacapavir may keep reliable HIV avoidance levels over 6 months.